Skip to main content
. 2015 May 7;3(3):e1033095. doi: 10.1080/23723556.2015.1033095

Figure 1.

Figure 1.

Genetically engineered mouse (GEM) models of BRAF-mutated melanoma display differential responses to inhibition of the mitogen activated protein kinase (MAPK) pathway and the phosphatidylinositol 3-kinase (PI3K) pathway. GEM models of the indicated genotype were treated with inhibitors of either the MAPK or the PI3K pathway, and the indicated tumor responses were noted.